Article Text
Abstract
Background/aims To characterise the morphology, location and functional significance of both macular and extramacular collateral vessels (CVs) in patients with a history of branch retinal vein occlusion (BRVO) using widefield swept-source optical coherence tomography angiography (WF SS OCTA).
Methods Patients with a history of BRVO underwent WF SS OCTA testing to acquire 12×12 mm images, which were evaluated for CVs and non-perfusion area (NPA). Region of interest analysis of individual CVs was performed to identify correlations between CV size, depth and retinal location. Mixed effects multivariate regression analyses of factors associated with NPA and visual acuity (VA) were performed.
Results Fifty-five CVs were identified in 28 BRVO eyes from 27 patients. CVs were identified in 42.9% (12/28) of eyes with a history of BRVO, and of these, 45.5% (25/55) were extramacular. The majority of CVs (87.3%, 48/55) coursed through both the superficial and the deep capillary plexus (DCP), while a subset (12.7%, 7/55) were strictly superficial. No CVs were found to course strictly through the DCP alone. CV depth increased with distance from the optic disc (p=0.011) and CV size increased with distance from the fovea (p=0.005). There were no statistically significant associations between CVs and NPA, or between CVs and VA.
Conclusions WF SS OCTA revealed that a large fraction of CVs that form after BRVO are extramacular, and the morphology of CVs varies as a function of retinal location. Depth-resolved study of CVs may offer valuable insights on the pathophysiological mechanisms leading to the development of macular oedema.
- retina
- imaging
Data availability statement
Data are available on reasonable request.
Statistics from Altmetric.com
Footnotes
Twitter @FVingopoulos, @itikagarg
NDR, FV and JCW contributed equally.
Presented at This work was presented in part at the Association for Research in Vision and Ophthalmology (ARVO), in May 2021
Contributors Concept and design: NR, FV, JW, NAP and JBM; acquisition, analysis or interpretation of data: NR, FV, JW, IG, YC, YZ, RL, RK and YL; drafting original manuscript: NR and FV, critically revising manuscript: NR, FV, JW, IG, YC, YZ, RL, RK, YL, NAP and JBM; obtained funding: JBM; supervision: JBM. NDR and JBM are guarantors.
Funding Lions International Fund (Grant 530 125 and 530869).
Competing interests NAP is a consultant for Alimera Sciences, Alcon, Allergan and Genentech. JBM is a consultant for Alcon, Allergan, Carl Zeiss, Sunovion and Genentech.
Provenance and peer review Not commissioned; externally peer reviewed.
Linked Articles
- Highlights from this issue